ES2962865T3 - Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical - Google Patents

Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical Download PDF

Info

Publication number
ES2962865T3
ES2962865T3 ES17807779T ES17807779T ES2962865T3 ES 2962865 T3 ES2962865 T3 ES 2962865T3 ES 17807779 T ES17807779 T ES 17807779T ES 17807779 T ES17807779 T ES 17807779T ES 2962865 T3 ES2962865 T3 ES 2962865T3
Authority
ES
Spain
Prior art keywords
azetidine
difluorophenoxy
compound
trifluorophenoxy
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17807779T
Other languages
English (en)
Spanish (es)
Inventor
Clas Sonesson
Fredrik Pettersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Integrative Res Laboratories Sweden AB
Integrative Research Laboratories Sweden AB
Original Assignee
Integrative Res Laboratories Sweden AB
Integrative Research Laboratories Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Res Laboratories Sweden AB, Integrative Research Laboratories Sweden AB filed Critical Integrative Res Laboratories Sweden AB
Application granted granted Critical
Publication of ES2962865T3 publication Critical patent/ES2962865T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17807779T 2016-11-18 2017-11-17 Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical Active ES2962865T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16199545 2016-11-18
PCT/EP2017/079666 WO2018091687A1 (en) 2016-11-18 2017-11-17 Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

Publications (1)

Publication Number Publication Date
ES2962865T3 true ES2962865T3 (es) 2024-03-21

Family

ID=57348567

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17807779T Active ES2962865T3 (es) 2016-11-18 2017-11-17 Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical

Country Status (10)

Country Link
US (1) US10875829B1 (enExample)
EP (1) EP3541784B1 (enExample)
JP (1) JP6990702B2 (enExample)
CN (1) CN109963834B (enExample)
DK (1) DK3541784T5 (enExample)
ES (1) ES2962865T3 (enExample)
FI (1) FI3541784T3 (enExample)
PL (1) PL3541784T3 (enExample)
PT (1) PT3541784T (enExample)
WO (1) WO2018091687A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112198237B (zh) * 2020-05-28 2021-08-06 扬子江药业集团广州海瑞药业有限公司 一种盐酸奈康唑杂质检测控制分析方法
CN121511082A (zh) 2023-07-06 2026-02-10 综合研究实验室瑞典股份公司 用于治疗和/或预防病理性淡漠的3-(2,3-二氟苯氧基)氮杂环丁烷或其药学上可接受的盐
EP4739654A1 (en) 2023-07-06 2026-05-13 Integrative Research Laboratories Sweden AB Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638939A2 (en) * 2003-06-24 2006-03-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2010022055A2 (en) * 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
WO2010058017A1 (en) 2008-11-24 2010-05-27 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
WO2010058019A1 (en) 2008-11-24 2010-05-27 Nsab, Filial Af Neurosearch Sweden Ab, Sverige 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
JP2012515760A (ja) 2009-01-20 2012-07-12 ファイザー・インク 置換ピラジノンアミド
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
AU2011218167B2 (en) * 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
KR101626681B1 (ko) 2011-06-07 2016-06-01 화이자 인코포레이티드 피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도
KR101273566B1 (ko) 2011-09-05 2013-06-11 한국과학기술연구원 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
EP2807163B1 (en) * 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
EP3186224B1 (en) 2014-08-27 2021-04-21 F. Hoffmann-La Roche AG Substituted azetidine derivatives as taar ligands
EP3215500A1 (en) * 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
HK1245251B (en) 2015-05-20 2020-04-24 综合研究实验室瑞典股份公司 Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
CN108026030B (zh) 2015-09-18 2020-10-09 正大天晴药业集团股份有限公司 一种氘代化合物的制备方法
TWI752098B (zh) * 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物

Also Published As

Publication number Publication date
US10875829B1 (en) 2020-12-29
PL3541784T3 (pl) 2024-03-11
EP3541784A1 (en) 2019-09-25
DK3541784T3 (en) 2023-10-23
WO2018091687A1 (en) 2018-05-24
JP6990702B2 (ja) 2022-01-13
CN109963834B (zh) 2023-04-14
FI3541784T3 (fi) 2023-10-02
PT3541784T (pt) 2023-11-22
JP2019535715A (ja) 2019-12-12
DK3541784T5 (da) 2024-09-16
CN109963834A (zh) 2019-07-02
EP3541784B1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
CN118027016A (zh) Parg抑制剂及其制备方法和用途
JP5716202B2 (ja) 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての3−フェニル−3−メトキシピロリジン誘導体
JP6990702B2 (ja) 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体
US20250042905A1 (en) Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
US10287247B2 (en) Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
JP5870031B2 (ja) 自動化放射合成
WO2025037013A1 (en) Diagnostic compounds that bind to alpha-synuclein
US12281116B2 (en) HTT modulators for treating Huntington's disease
HK1245251A1 (en) Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
TW201245197A (en) Substituted [(5h-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists
MX2011005034A (es) Nuevos derivados de 3-fenil-azetidina utiles como moduladores de la neurotransmision catecolaminergica cortical.
HK40092922A (en) Vmat2 inhibitors and methods of use
HK40092922B (en) Vmat2 inhibitors and methods of use
CN113727713A (zh) 氟取代的2-氨基噻唑-5-芳香族甲酰胺的用途
HK1233257A1 (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors